Form 4 for TXG 10x Genomics, Inc.
Accepted 2023-11-27 00:00:00 ET · period of report 2023-11-22 · accession 0001610717-23-000364 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-11-27 | 2023-11-22+ | TXG | Saxonov Serge | CEO, Dir | S - Sale | $43.53 | -7,480 | 847.4K | -0.9% | -$325.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-11-22 | S | D | 3,757 | $43.34 | 851,169 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-11-24 | S | D | 3,723 | $43.72 | 847,446 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $43.65 to $43.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |